Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease
2006

Understanding Alport Syndrome and Potential Treatments

publication Evidence: moderate

Author Information

Author(s): Raghu Kalluri, Michael Zeisberg

Hypothesis

Does the failure to switch collagen isoforms in Alport syndrome make the glomerular basement membrane more susceptible to degradation by matrix metalloproteinases?

Conclusion

MMP inhibitors may delay disease progression in early stages of Alport syndrome but could worsen outcomes if used later.

Supporting Evidence

  • Alport syndrome affects one in 50,000 live births in the U.S.
  • The GBM in Alport syndrome is more susceptible to degradation by MMPs.
  • MMP inhibitors delayed disease progression in early-stage mice.

Takeaway

Alport syndrome is a kidney disease that can get worse over time, but some medicines might help if given early.

Methodology

The study used a mouse model lacking functional α3(IV) collagen to investigate the role of MMPs in disease progression.

Limitations

The findings are based on animal models, which may not fully translate to human patients.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0030154

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication